Bright Minds Biosciences Inc.
DRUG
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 100.98% | 111.31% | 82.59% | 74.68% | 32.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 326.84% | 647.64% | 1,315.68% | 549.12% | -5.05% |
| Operating Income | -326.84% | -647.64% | -1,315.68% | -549.12% | 5.05% |
| Income Before Tax | -15,429.38% | -423.06% | -2,355.60% | -382.70% | 102.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15,429.38% | -423.06% | -2,355.60% | -382.70% | 102.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15,429.38% | -423.06% | -2,355.60% | -382.70% | 102.86% |
| EBIT | -326.84% | -647.64% | -1,315.68% | -549.12% | 5.05% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -12,366.67% | -223.68% | -1,522.61% | -206.18% | 101.77% |
| Normalized Basic EPS | -12,238.89% | -223.61% | -1,522.55% | -206.21% | 101.79% |
| EPS Diluted | -12,366.67% | -226.20% | -1,565.48% | -203.53% | 101.76% |
| Normalized Diluted EPS | -13,342.42% | -223.61% | -1,522.55% | -206.21% | 101.64% |
| Average Basic Shares Outstanding | 25.88% | 61.65% | 58.70% | 57.68% | 60.45% |
| Average Diluted Shares Outstanding | 16.86% | 61.65% | 58.70% | 57.68% | 72.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |